Premium
India and Southeast Asia-focused Quadria Capital is preparing to exit a biotech portfolio firm as deals in the broader pharmaceuticals space gain traction because of the pandemic. Quadria Capital is preparing to exit its 20% stake in Concord Biotech and has shortlisted Kotak Mahindra Bank and Torreya Partners to run ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
